Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense

Kong, Yuanyuan; You, Hong; Jia, Jidong

doi:10.1007/s12072-016-9714-9

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the preventive efficacy of antiviral therapy can be translated to general population; for example, since launched in 2003, a viral hepatitis therapy program has significantly reduced incidence and mortality of HCC in the general population of Taiwan (HR was 0.86 for HCC incidence and 0.76 for HCC mortality) [134]. Of note is that suppression of viral replication in chronic hepatitis B patients by antiviral treatment could reduce but not eliminate the risk of HCC, especially in patients with cirrhosis [135–137]. Kim et al.…”

Section: Preventionmentioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

Self Cite

View full text Add to dashboard Cite

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

show abstract

Section: Preventionmentioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sustained complete viral suppression, ALT normalization and improvement of liver histology can be achieved by treatment of finite duration with Peg‐IFN or by NA maintenance treatment. Antiviral therapy significantly reduces but does not eliminate the risk of HCC development, particularly in cirrhotic patients …”

Section: Definition Of Cure and Its Key Challengesmentioning

confidence: 99%

Roadmap to functional cure of chronic hepatitis B: An expert consensus

Ning

Wang

Ren

et al. 2019

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection continues to be a major public health issue worldwide. HBsAg loss is associated with functional remission and improved long-term outcome, and is considered to be a 'functional cure' (also referred to as clinical or immunologic cure) for chronic hepatitis B. This ideal goal of therapy can be achieved using optimized combination regimens with direct-acting antivirals [eg nucleos(t)ide analogues (NAs)] and immunomodulators [eg pegylated interferon alpha2a (Peg-IFN)] in selected patients with chronic hepatitis B. Among different combination therapies currently available, those with NA lead-in followed by Peg-IFN in virally suppressed patients has been demonstrated to be effective. This review provides an updated overview of the evidence supporting the use of combination therapies and summarizes expert consensus on the roadmap to attain functional cure for chronic hepatitis B patients. K E Y W O R D S chronic hepatitis B, combination therapy, consensus, functional cure, HBsAg loss | 1147 NING et al.

show abstract

“…8,9 For the treatment of CHB, even the most widely used nucleoside analogues or interferon can not achieve the cure of the disease. 10,11 The above mentioned therapies of CHB to restore the immune function of the body and improve the T cell response may be an important target for the treatment of CHB in the future. There are many immunotherapies at present, but the toxic and side effects of its immune preparations, technology, cost etclimit the implementation of its research.…”

Section: Introductionmentioning

confidence: 99%

Study on the Characteristics of Gut Microbiota in Chronic Hepatitis B Patients With Damp Heat Syndrome and Liver Depression and Spleen Deficiency Syndrome

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To explore the potential biological characteristics of traditional Chinese medicine(TCM) syndromes in CHB patients is of great significance to improve the level of TCM treatment.This study was designed to explore the characteristics of gut microbiota in CHB patients with two most common TCM Syndromes.Methods: According to the diagnostic criteria of Western medicine, TCM and screening exclusion criteria, 65 cases of CHB patients with damp heat syndrome and 28 cases of CHB patients with liver depression and spleen deficiency syndrome were finally included in the study. All the basic information was gathered and the fresh fecal samples were collected for 16S rDNA sequencing. 16S rDNA of gut microbiota was sequenced using Illumina hiseq 2500 high-throughput sequencing platform.Based on the optimized sequence, OTU clustering analysis and taxonomic annotation were carried out. Results: The difference in relative abundance of gut microbiota was significant between damp heat syndrome and liver depression and spleen deficiency syndrome in CHB patients. Cyanobacteria was only found in damp heat syndrome.The relative abundance of Erysipelotrichia and Subdoligranulum were higher in liver depression and spleen deficiency syndrome,while the relative abundance of Rhodospirillales, Alphaproteobacteria,and Lachnospira were higher in the damp heat syndrome.LEfSe analysis showed that Lachnospira,Olsenella and Subdoligranulum had significant difference in species among the two TCM syndromes.Conclusions: The different characteristics of gut microbiota in the two TCM syndromes of CHB patients may play an important role in syndrome formation of TCM,which provides a new field of vision for the accurate diagnosis and treatment of TCM.

show abstract

Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense

Cited by 4 publications

References 24 publications

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Roadmap to functional cure of chronic hepatitis B: An expert consensus

Study on the Characteristics of Gut Microbiota in Chronic Hepatitis B Patients With Damp Heat Syndrome and Liver Depression and Spleen Deficiency Syndrome

Contact Info

Product

Resources

About